Avestar Capital, LLC Biomarin Pharmaceutical Inc Transaction History

Avestar Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $50,550 - $63,832	-750 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$80.35 - $93.9 $16,230 - $18,967	202 Added 36.86%	750 $44,000
Q1 2019 May 09, 2019	SELL	$84.2 - $98.62 $2,105 - $2,465	-25 Reduced 4.36%	548 $27,000
Q4 2018 Jan 25, 2019	SELL	$80.14 - $106.07 $2,724 - $3,606	-34 Reduced 5.6%	573 $28,000
Q3 2018 Oct 23, 2018	BUY	$93.92 - $105.72 $6,198 - $6,977	66 Added 12.2%	607 $38,000
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $39,905 - $51,990	525 Added 3281.25%	541 $32,000
Q1 2018 May 10, 2018	BUY	$77.67 - $92.63 $1,242 - $1,482	16 New	16 $1,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Avestar Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Avestar Capital, LLC with notifications on news.